Microarrays in Blood Group Genotyping

Boccoz, S.A.; Goff, Gaëlle Le; Blum, Loı̈c J.; Marquette, Christophe A.

doi:10.1007/978-1-4939-2690-9_9

Cited by 4 publications

(5 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Therefore, NGS is a highly suitable approach for identifying rare and mutant blood types with no known specific antibodies (110,111). The microarray technology (112) can simultaneously identify numerous SNPs and alleles of different blood group systems, thereby allowing genotyping of multiple blood group systems. In addition, the microarray technology generally involves high throughput automated and can detect and analyze a large number of blood group DNA polymorphisms (112,113).…”

Section: Genotypingmentioning

confidence: 99%

“…The microarray technology (112) can simultaneously identify numerous SNPs and alleles of different blood group systems, thereby allowing genotyping of multiple blood group systems. In addition, the microarray technology generally involves high throughput automated and can detect and analyze a large number of blood group DNA polymorphisms (112,113). However, the sensitivity of the microarray chip decreases after repeated use, sample preparation, and labeling are technically demanding, and it can only detect known alleles.…”

Section: Genotypingmentioning

confidence: 99%

See 1 more Smart Citation

Blood Group Testing

Guo

2022

Front. Med.

View full text Add to dashboard Cite

Red blood cell (RBC) transfusion is one of the most frequently performed clinical procedures and therapies to improve tissue oxygen delivery in hospitalized patients worldwide. Generally, the cross-match is the mandatory test in place to meet the clinical needs of RBC transfusion by examining donor-recipient compatibility with antigens and antibodies of blood groups. Blood groups are usually an individual's combination of antigens on the surface of RBCs, typically of the ABO blood group system and the RH blood group system. Accurate and reliable blood group typing is critical before blood transfusion. Serological testing is the routine method for blood group typing based on hemagglutination reactions with RBC antigens against specific antibodies. Nevertheless, emerging technologies for blood group testing may be alternative and supplemental approaches when serological methods cannot determine blood groups. Moreover, some new technologies, such as the evolving applications of blood group genotyping, can precisely identify variant antigens for clinical significance. Therefore, this review mainly presents a clinical overview and perspective of emerging technologies in blood group testing based on the literature. Collectively, this may highlight the most promising strategies and promote blood group typing development to ensure blood transfusion safety.

show abstract

Section: Genotypingmentioning

confidence: 99%

Section: Genotypingmentioning

confidence: 99%

Blood Group Testing

Guo

2022

Front. Med.

View full text Add to dashboard Cite

show abstract

“…Low-, medium-and high-throughput techniques have been developed for blood group genotyping and in the last decade we have seen a great expansion and evolution of the technologies available [6][7][8][9][10][11][12]. Thus, molecular testing is rapidly advancing and offers tremendous help as a powerful tool with potential advantages in the identification of rare RBC donors and finding antigen matches for chronically transfused patients [7,[13][14][15][16][17].…”

Section: Introductionmentioning

confidence: 99%

Discrepancies between red cell phenotyping and genotyping in daily immunohematology laboratory practice

Menegati¹,

Santos

Macedo

et al. 2020

Transfusion and Apheresis Science

View full text Add to dashboard Cite

False-positive and false-negative reactions exist for serological and molecular antigen typing methods. If the predicted phenotype is inconsistent with the patient`s known antibodies or serological phenotype, the discrepancy must be investigated. False-negative and false-positive results are clinically problematic in blood donors and patients. In this study, we investigated discrepant results between serology and molecular testing in patients and blood donors that occurred in daily molecular laboratory practice over a two year-period. SCD patients represented a large percentage of our cases of discrepancies but we also observed a high prevalence of discrepancies between phenotypes and genotypes in blood donors. The main reasons that led to discrepancies were recent transfusions and limitations of phenotyping. Discrepancies classified as false positive phenotype/ true negative genotype and false negative phenotype/true positive genotype occurred mainly in patients with recent transfusions and individuals with RH variants while those classified as true negative phenotype/false positive genotype involved null phenotypes due to silent genes. Despite the limitations of molecular methods currently employed, we found more false-negative and false-positive phenotypes than genotypes demonstrating that genotyping is more efficient to define the blood types, especially in transfusion dependent patients.

show abstract

“…Dobór długości sond i ustalenie warunków inkubacji dla zajścia swoistego związania sond i warunków odpłukania niezwiązanego DNA jest najtrudniejszym wyzwaniem dla zespołów opracowujących i produkujących takie testy. Badane DNA poddaje się procesowi namnożenia fragmentów genów kodujących antygeny, a następnie poddaje hybrydyzacji z zestawem swoistych sond [26].…”

Section: Mikromacierzeunclassified

Rozwój technologii opartych na metodach biologii molekularnej do oznaczania grup krwi

Guz

Orzińska

Brojer

2019

Journal of Transfusion Medicine

View full text Add to dashboard Cite

Zakład Immunologii Hematologicznej i Transfuzjologicznej Instytutu Hematologii i Transfuzjologii w Warszawie Streszczenie W ciągu ostatnich lat obserwuje się gwałtowny rozwój technologii badań molekularnych stosowanych w immunohematologii. Na świecie są one obecnie używane nie tylko przez laboratoria referencyjne i wysokospecjalistyczne, lecz są wdrażane do badań masowych w centrach krwiodawstwa, gdzie służą przede wszystkim do genotypowania klinicznie istotnych antygenów w celu zwiększenia dostępności dawców dla chorych z alloprzeciwciałami. W nieodległej przyszłości będzie też możliwe dobieranie dla chorych zależnych od przetoczeń dawców zgodnych w najbardziej immunogennych antygenach, tak by zapobiegać alloimmunizacji. Z myślą o tak ambitnych planach, są opracowywane na świecie zaawansowane technologie, umożliwiające masowe genotypowanie antygenów komórek krwi. W niniejszym artykule zostaną omówione metody biologii molekularnej przydatne dla takich badań. Słowa kluczowe: genotypowanie antygenów komórek krwi, nanofluidowa/cyfrowa reakcja łańcuchowa polimerazy, mikromacierze, spekrometria masowa MALDI-TOF, multipleksowa amplifikacja zależna od ligacji sond (MLPA), sekwencjonowanie następnej generacji (NGS)

show abstract

Microarrays in Blood Group Genotyping

Cited by 4 publications

References 6 publications

Blood Group Testing

Blood Group Testing

Discrepancies between red cell phenotyping and genotyping in daily immunohematology laboratory practice

Rozwój technologii opartych na metodach biologii molekularnej do oznaczania grup krwi

Contact Info

Product

Resources

About